Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

CDER’s Hanan Ghantous discusses PINDs, INDs and NDAs/BLAs, and the FDA’s roles and responsibilities related to nonclinical safety assessment (pharmacology/toxicology) in detail. He provides case studies and a comparison of the development of biologic drugs vs. small molecule drugs will be presented.

_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming training and free continuing education credits: https://www.fda.gov/cdersbia

CDER SBIA 2018 Playlist:    • 2018 CDER Small Business and Industry...  
LinkedIn:   / cder-small-business-and-industry-assistance  
Training resources: https://www.fda.gov/cderbsbialearn

Twitter:   / fda_drug_info  

CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367